Gsa Capital Partners LLP Verona Pharma PLC Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Gsa Capital Partners LLP holds 20,526 shares of VRNA stock, worth $1.55 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
20,526
Previous 53,372
61.54%
Holding current value
$1.55 Million
Previous $2.48 Million
47.44%
% of portfolio
0.12%
Previous 0.18%
Shares
6 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$495 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$416 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$296 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$261 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$218 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.6B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...